重组人内皮抑素对小鼠肺腺癌LA795的抑制作用

目的观察重组人内皮抑素(rhES)对小鼠肺腺癌LA795生长和转移的抑制作用。方法对ThES高效表达克隆pCX的表达产物进行纯化,得到ThES。将LA795肺腺癌细胞接种于T739小鼠背部皮下,随机分成2组,接种后第10天起分别给予rhES20mg/kg·b.w.或等体积PBS缓冲液皮下注射,1次/d,共14d。观察2组肿瘤生长情况、肺湿重、肺表面转移结节数、动物生存时间,分别进行t检验。结果治疗前后rhES组肿瘤体积分别为(650±201)mm3、(1642±211)mm3;而PBS组肿瘤体积由治疗前的(623±248)mm3增至(9194±952)mm3。rhES组肺湿重、肺表面转移结节数明显少于PBS组,动物生存时间明显延长(P<0.01)。结论rhES可明显抑制LA795所致的小鼠实验性肿瘤的生长与转移,延长动物的生存时间。     

Somatic mutations of the EGF receptor and their signal transducers affect the efficacy of EGF receptor-specific tyrosine kinase inhibitors

Non-small cell lung cancer (NSCLC) is a major subtype of lung cancer that has been the most common and most fatal cancer worldwide. Gefitinib (Iressa) and erlotinib (Tarceva) specific tyrosine kinase inhibitors (TKI) for the epidermal growth factor receptor (EGFR), have been demonstrated to be effective for some NSCLC patients and are pioneering molecular-targeted drugs used in the clinic for cancer. Because many studies indicate that only some patient populations benefit from these drugs, there has been an urgent need to develop diagnostic methods to select appropriate patients for whom treatment with these drugs will be beneficial. Moreover, problems of acquired resistance after long-term treatment with the drugs have emerged. In this review, I summarize the current understanding of the EGFR-activated signal transduction pathway, which plays important roles in tumorigenesis, and of the molecular mechanisms that determine the sensitivity toward EGFR-TKI.